Molecular profiling to predict hepatocellular carcinoma outcome

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 2, 2009, Pages 101-103

  Hoshida, Yujin ^a   Villanueva, Augusto ^b   Llovet, Josep M ^b,c,d  

^a HARVARD UNIVERSITY   (United States)

^b Translational Research Laboratory   (Spain)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; INTERLEUKIN 6; TUMOR MARKER;

CANCER RECURRENCE; CANCER STAGING; DISEASE COURSE; EDITORIAL; GENE EXPRESSION PROFILING; GENE TARGETING; HUMAN; LIVER CELL CARCINOMA; LIVER FIBROSIS; LIVER FUNCTION TEST; PHENOTYPE; PROGNOSIS; PROTEIN BLOOD LEVEL; RECURRENCE RISK; TUMOR VOLUME; GENETICS; LIVER TUMOR; METABOLISM; RISK FACTOR; TUMOR RECURRENCE;

ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; GENE EXPRESSION PROFILING; HUMANS; INTERFERONS; INTERLEUKIN-6; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NF-KAPPA B; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 67649871095     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.5     Document Type: Editorial

References (21)

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362(9399), 1907-1917 (2003).
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7), 2557-2576 (2007).
3. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378-390 (2008).
4. Imamura H, Matsuyama Y, Tanaka E et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J. Hepatol. 38(2), 200-207 (2003).
5. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 42(5), 1208-1236 (2005).
6. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin. Liver Dis. 25(2), 181-200 (2005).
7. Sherman M. Recurrence of hepatocellular carcinoma. N. Engl. J. Med. 359(19), 2045-2047 (2008).
8. Hoshida Y, Villanueva A, Kobayashi M et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 359(19), 1995-2004 (2008).
9. Chen YJ, Yeh SH, Chen JT et al. Chromosomal changes and clonality relationship between primary and recurrent hepatocellular carcinoma. Gastroenterology 119(2), 431-440 (2000).
10. Ng IO, Guan XY, Poon RT, Fan ST, Lee JM. Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. J. Pathol. 199(3), 345-353 (2003).
11. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol. 48(Suppl. 1), S20-S37 (2008).
12. Colombo M, de Franchis R, Del Ninno E et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N. Engl. J. Med. 325(10), 675-680 (1991).
13. Sangiovanni A, Del Ninno E, Fasani P et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126(4), 1005-1014 (2004).
14. Ye QH, Qin LX, Forgues M et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat. Med. 9(4), 416-423 (2003).
15. Iizuka N, Oka M, Yamada-Okabe H et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 361 (9361), 923-929 (2003).
16. Lee JS, Chu IS, Heo J et al. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 40(3), 667-676 (2004).
17. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br. J. Surg. 60(8), 646-649 (1973).
18. Coussens LM, Werb Z. Inflammation and cancer. Nature 420(6917), 860-867 (2002).
19. Budhu A, Forgues M, Ye QH et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10(2), 99-111 (2006).
20. Stegmaier K, Ross KN, Colavito SA et al. Gene expression-based high-throughput screening (GE-HTS) and application to leukemia differentiation. Nat. Genet. 36(3), 257-263 (2004).
21. Lippman SM. The future of molecular-targeted cancer chemoprevention. Gastroenterology 135(6), 1834-1841 (2008).